Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
[HTML][HTML] Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With≥ 2 HER2-Directed …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
METHODS Patients, including those with stable, asymptomatic CNS disease, were randomly
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
assigned 1: 1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m 2 twice a …
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With≥ 2 HER2-Directed Regimens …
C Saura, M Oliveira, YH Feng… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Phase …
NALA Investigators - Journal of Clinical Oncology, 2020 - scholars.northwestern.edu
PURPOSE NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With≥ 2 HER2-Directed Regimens …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - europepmc.org
Purpose NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With≥ 2 HER2-Directed Regimens …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - escholarship.org
PurposeNALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With≥ 2 HER2-Directed Regimens …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> NALA (ClinicalTrials. gov
identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing …
identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing …
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Phase …
NALA Investigators - Journal of Clinical Oncology, 2020 - researchoutput.ncku.edu.tw
PURPOSE NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With≥ 2 HER2-Directed Regimens …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - hub.hku.hk
PURPOSE: NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Phase …
C Saura, M Oliveira, YH Feng, MS Dai… - JOURNAL OF …, 2020 - iris.unina.it
PURPOSE NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …